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Abstract
Increasingly, medical research is dependent on data collected for non-research purposes, such as
electronic health records data (EHR). EHR data and other large databases can be prone to measurement
error in key exposures, and unadjusted analyses of error-prone data can bias study results. Validating a
subset of records is a cost-effective way of gaining information on the error structure, which in turn can
be used to adjust analyses for this error and improve inference. We extend the mean score method for the
two-phase analysis of discrete-time survival models, which uses the unvalidated covariates as auxiliary
variables that act as surrogates for the unobserved true exposures. This method relies on a two-phase
sampling design and an estimation approach that preserves the consistency of complete case regression
parameter estimates in the validated subset, with increased precision leveraged from the auxiliary data.
Furthermore, we develop optimal sampling strategies which minimize the variance of the mean score
estimator for a target exposure under a fixed cost constraint. We consider the setting where an internal
pilot is necessary for the optimal design so that the phase two sample is split into a pilot and an adaptive
optimal sample. Through simulations and data example, we evaluate efficiency gains of the mean score
estimator using the derived optimal validation design compared to balanced and simple random sampling
for the phase two sample. We also empirically explore efficiency gains that the proposed discrete optimal
design can provide for the Cox proportional hazards model in the setting of a continuous-time survival
outcome.
Keywords: Mean score method, Neyman allocation, pilot study, adaptive design, measurement error, surro-
gate variable, auxiliary variable
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1 Introduction
Error-prone exposures are common in many epidemiological settings, such as clinical studies relying on
electronic health records, medical claims data, or large observational cohort studies where a gold standard
measure was not collected on all subjects. In some cases, a validation subset is available, in which observa-
tions without error can be obtained on a subset of subjects and used to inform measurement error correction
methods. Two-phase sampling has been widely used for a number of settings in clinical and epidemio-
logical studies with budgetary constraints. The first sampling phase includes readily available data (e.g.,
electronic health records data) on all study subjects, and the second phase includes additional information
on a subsample of records (e.g., extensive chart validation of a key exposure variable).
The efficiency of two-phase sampling can vary substantially based on the selection of the second phase
sample. For logistic regression, Breslow and Chatterjee (1999) showed stratification of the phase two sample
on the outcome and covariates with equal numbers per stratum performed well and better than stratifying on
the outcome or covariates alone. When the outcome and error-prone exposure are discrete, the mean score
method (Reilly and Pepe, 1995; Reilly, 1996) can be used to derive regression parameter estimates that
have been corrected for measurement error and can improve efficiency over the complete case analysis by
incorporating information from auxiliary data. Further, these authors developed an optimal sampling strat-
egy for the mean score estimator to find the proportion allocated into each outcome-exposure stratum of the
validation sample that can minimize cost for a fixed variance or minimize the variance of a target regression
parameter for a fixed validation subset size, studying the performance of this method for a binary outcome
and covariate. McIsaac and Cook (2014) compared response-dependent two-phase sampling designs for the
setting of a binary outcome when both the true and auxiliary covariate were also binary. They found that
the mean score estimator was an efficient approach, even when the model used to derive the optimal design
was misspecified. They also found that the mean score optimal design improved the efficiency of other
estimation approaches, such as maximum likelihood.
For survival outcomes, however, the focus of most of the previous work on two phase sampling has
been on estimation and hypothesis testing and not design. Lawless (2018) reviews two-phase estimators for
outcome dependent sampling and failure time data, and mentions that efficiency can be gained by sampling
extremes of the outcome those with early events and late censoring. Tao et al. (2019) develop an optimal
two-phase sampling designs for a general regression model framework, but these designs are only optimal
under the null assumption that the regression coefficient for the expensive/mis-measured exposure of interest
is zero. While this framework in principle applies to the Cox proportional hazards regression model, these
designs require estimation of several nuisance parameters related to the conditional distribution of expensive
covariate given the surrogate, as well as a potentially infinite dimensional nuisance parameter related to the
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log-partial likelihood; and their performance have not yet been studied for survival outcomes.
In this study, we consider an extension of the mean score method to handle survival outcomes, in which
error prone exposures are treated as auxiliary variables. The mean score approach is appealing because it
is intuitive and offers a straightforward method to implement an optimal design (Whittemore and Halpern,
1997). In order to take advantage of the mean score approach, we will first consider a discrete-time survival
model, but will also consider how the derived optimal design can be advantageous for a continuous time
analysis. Discrete survival data are natural for settings where the occurrence of an event is monitored
periodically and occur frequently in clinical studies where there is routine follow-up at fixed intervals. We
develop an application of the mean score method to the discrete proportional hazards model. We will also
extend the work of Reilly (1996) to derive an optimal sampling design for the validation subset, which
minimizes the variance of the regression parameter estimation for a given size of the validation subset. This
approach requires an estimate of several nuisance parameters in the absence of external estimates, which
can be estimated with internal pilot data. We consider a multi-wave sampling strategy that in the first wave
obtains a pilot phase two sample to estimate the parameters necessary to derive the optimal design and then
for the second wave adopts an adaptive sampling strategy for the remaining phase two subjects to achieve
the optimal allocation. McIsaac and Cook (2015) considered a similar approach for binary outcomes.
We compare the relative efficiency of our mean score estimator under simple random sampling, balanced
sampling and the proposed optimal design. We also examine the efficiency gains of the mean score approach
over the complete case estimator of the validated data. The proposed method is further illustrated with data
from the National Wilms Tumor Study (NWTS). In the NWTS, the true validated exposure was measured
on everyone, allowing the evaluation of different two-phase sampling strategies on the precision of the final
study estimates in this applied setting. In the context of this example, which had a continuous survival
outcome, we study the efficiency gains of using the proposed optimal design of the discretized outcome
for the usual continuous-time analysis. We also investigate how different allocations of the pilot sample
affect the efficiency gains of the mean score estimator, depending on how individuals with censored versus
observed outcomes are sampled. Finally, we provide some concluding remarks on the advantages of the
mean score estimator in this setting and discuss directions for future work.
2 The mean score method for discrete-time survival models
2.1 Setup and notation for the discrete-time model
Let T be a discrete random variable. Denote the j-th discrete value of T by tj and write λ0j = λ0(tj),
where λ0 is the baseline hazard function for T defined by λ0(tj) = P (T = tj |T ≥ tj) for j ∈ J , where
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J is the index set for the discrete times with positive mass. We assume the time to event response T is
associated with a d-dimensional covariate vector X = (X1, . . . , Xd)> such that the conditional hazard
function λ(t|x) = P (T = t|T ≥ t, X = x) is given by
g
(
λ(t|x)) = g(λ0(t)) exp(β>x) (t ∈ T ) (2.1)
for some coefficient vector β = (β1, . . . , βd)>, where g : [0, 1] → R is a monotone transformation and
T = {tj : j ∈ J}. For example, the odds transformation g1(u) = u1−u yields the logit hazard model, where
logit
(
λj(x)
)
= αj + β
>x for αj = logit(λ0j) and λj(x) = λ(tj |x). It follows that the likelihood function
under the logit hazard model has the same representation with the logistic regression model such that the
number of events at a time tj represents binomial outcomes with probability λj(x) for each j ∈ J (Meier
et al., 2003). The complementary log transformation g2(u) = − log(1−u) gives a proportional log-survival
model log
(
Sj(x)
)
= log(S0j) exp(β
>x), where Sj(x) = P (T ≥ tj |X = x) and S0j = S0(tj) for the
baseline survival function S0 for T . Kalbfleisch and Prentice (2011) provide further details.
We consider that T may be subject to random censoring prior to the finite maximum follow-up time of
τ < ∞. For a random censoring time C, independent of T , let Y = min{T,C} be the observed censored
survival time and ∆ = I(T ≤ C) be the event indicator. We assume that XN = {(Yi,∆i,Xi) : 1 ≤
i ≤ N} are independent and identically distributed and will not be completely observed on all subjects as
N -random copies of (Y,∆,X). Instead, XI,N = {(Yi,∆i,Zi) : 1 ≤ i ≤ N} are the data available for all
subjects in the first phase of a study, where Z = (Z1, . . . , Zq)> are discrete surrogates or auxiliary variables
associated with X. Complete data for the likelihood are observed on the phase two sample, denoted by
XII,n = {(Yi,∆i,Xi) : i ∈ I}, where I is a subset of {1, . . . , N} having the cardinality of n. For example,
the auxiliary variables Z might be error-prone discrete measures of X while X may or may not be discrete.
We also allow for settings where some components of X are available on all subjects, such as sex or other
demographic information ascertained in the first phase of the study. For this setting, we may introduce
a slight abuse of notation writing X = (XC ,XI) and Z = (XC ,A), where XC are the components of
Xi observed on everyone, XI are the incomplete components of X not observed at the phase one, and A
indicates a generic notation for auxiliary variables in the first phase of the study. In this case, I denotes the
set of subject indices for which the true covariates X are fully observed, with XI sampled in the second
phase of the study, and the auxiliary phase one variables are limited to A (Reilly and Pepe, 1995; McIsaac
and Cook, 2015).
Unlike previous literature (Lawless et al., 1999; Chatterjee et al., 2003; Chatterjee and Chen, 2007; Tao
et al., 2017), we note that the model (2.1) does not include auxiliary variables as predictors, but rather Z is
a surrogate by the Prentice criterion (Prentice, 1989). That means the likelihood function L1(θ;Y,∆,X,Z)
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equals L1(θ;Y,∆,X), where θ is the collection of parameters involved in (2.1). Thus, the complete infor-
mation for θ is carried by (Y,∆,X), while E{logL1(θ;Y,∆,X) |Y,∆,Z}may represent extra information
of (Y,∆,Z) compared to likelihood-based inference using only complete case data for (Y,∆,X). In this
paper, we consider the mean score method, which is valid when the validation subset I for the phase two
sample is randomly chosen from the full cohort given information obtained from the first phase of a study.
Therefore, we use the log-likelihood from all available observations written by
∑
i∈I
logL1(θ;Yi,∆i,Xi) +
∑
i∈Ic
∫
logL1(θ;Yi,∆i,x)h(x|Zi) dx, (2.2)
where h(x|z) denotes the conditional density function of X given Z = z and Ic = {1, . . . , N}\I indicates
a set of (N −n) indices for individuals whose complete covariates are not available. For an individual i and
time j, we define the observed event indicator Dij = I(Yi = tj , ∆i = 1) and denote subject i’s censored
survival time index by J(i) = arg{j ∈ J : Yi = tj} for 1 ≤ i ≤ n. Thus, Dik = 0 for all k < J(i). Then,
it follows that the log-likelihood function given (Yi,∆i,Xi) can be written by
logL1(θ;Yi,∆i,Xi) =
J(i)∑
j=1
[
Dij log
( λj(Xi)
1− λj(Xi)
)
+ log
(
1− λj(Xi)
)]
, (2.3)
for each 1 ≤ i ≤ n. In the above equation, we used the fact that L1(θ;Y,∆,X) = S(Y |X)λ(Y |X)∆(1−
λ(Y |X))1−∆ and the conditional survival function Sj(x) = P (T ≥ tj |X = x) was calculated by
∏j−1
k=1(1−
λk(x)) for j ≥ 2, together with S1(x) = 1 by definition.
2.2 The mean score method
We apply the mean score method (Reilly and Pepe, 1995; Reilly, 1996) to the conditional hazard model (2.1)
when auxiliary variables are discrete. Employing the Expectation-Maximization (EM) technique (Dempster
et al., 1977) with (2.2) and (2.3), we may find the maximum likelihood estimator of θ. However, h(x|z)
is generally unknown and a parametric approach for the estimation of h(x|z) may result in inconsistent
inference of θ in likelihood-based methods. Lawless et al. (1999) introduced a semi-parametric method,
estimating the conditional density function h(x|z) nonparametrically, such that the integration in (2.2) is
replaced with a single-step approximation (McIsaac and Cook, 2014). Following the mean score approach,
for those not in the phase two subset, we can replace the unobserved score contribution based on X with its
expected value based on the observed phase one data. By replacing the expected value to an empirical mean,
the semi-parametric estimation of θ can then be achieved by maximizing an inverse probability weighted
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log-likelihood
QN (θ) =
∑
i∈I
J(i)∑
j=1
pˆi(Yi,∆i,Zi)
−1
[
Dij log
( λj(Xi)
1− λj(Xi)
)
+ log
(
1− λj(Xi)
)]
, (2.4)
where pˆi(Yi,∆i,Zi) is an empirical estimate of pi(Yi,∆i,Zi), the sampling probability of the i-th individual
selected into the validation subset, which can be consistently estimated by n(Yi,∆i,Zi)/N(Yi,∆i,Zi) as
n and N increase. Here, n(y, δ, z) is the number of subjects in I who have the same observations with
(y, δ, z) in the first phase study; N(y, δ, z) is defined similarly to n(y, δ, z) with replacement of the index
set I with {1, . . . , N} of the full sample.
We note that Flanders and Greenland (1991) also proposed a similar estimating equation to (2.4) based
on the pseudo-likelihood method, which coincides to the filling in method introduced by Vach and Blettner
(1991) when X is categorical. However, depending on the choice of transformation g in (2.1), different
forms of score equations follow from the above weighted log-likelihood (2.4). In Supplementary Material
Section A.2, we provide the detailed forms of the mean score equations and the associated Hessian matrices
when the logit transformation g1 and the complementary log transformation g2 are used.
2.3 Connection to the Cox model for a continuous-time outcome
Our expectation that the optimal design for our discrete time proportional hazards model will also be ad-
vantageous for the continuous time Cox model is based on the connection between the parameters in these
two models. For this, we briefly review this connection. For further discussion, see Kalbfleisch and Prentice
(2011).
From the log-likelihood (2.3), we note that the logit hazard model is the canonical form of the discrete-
time survival model (2.1) under the odds transformation g1(u) = u1−u , such that logit(λj(x)) = αj + β
>x,
where αj = logit(λ0j) is the logit transformation of the baseline hazard. However, we also note that any
model with an arbitrary monotone transformation in (2.1) leads to a reparameterization of the logit hazard
model. For example, suppose the complementary log transformation g2(u) = − log(1 − u) defines the
true survival model. Then it can be easily seen that logit(λj(x)) = exp
(
eαj+β
>x) − 1, where αj =
log(− log(1−λ0j)) is the complementary log-log transformation of the baseline hazard, and the application
of chain rules to (2.3) is followed by likelihood-based estimation of θ = (α,β), which is also equivalent to
reparameterization of the logit hazard model.
In particular, if usual continuous-time Cox proportional hazards are grouped into discrete disjoint inter-
vals, this will lead to the conditional hazard model (2.1) for discrete-time outcomes with the complementary
log transformation. To be specific, let λC(t|x) be the conditional hazard function in the Cox model for the
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continuous-time survival outcome such that λC(t|x) = λC0 (t) exp(β>x), where λC0 is the associated base-
line hazard function. Suppose we are only able to observe survival outcomes censored by disjoint intervals
(tj−1, tj ] with t0 ≡ 0, so that statistical inference on conditional hazards by each interval is a goal of the
study. Then, we may denote the conditional hazards on the j-th interval by
λj(x) = P (T ≤ tj |T > tj−1,X = x). (2.5)
for each j ∈ J . Since the conditional survival function SC(t|x) = P (T > t |X = x) is equivalent to
exp
( − ∫ t0 λC(s|x) ds) in the Cox model, we note that − log (1 − λj(x)) = ∫ tjtj−1 λC(s|x) ds represents
the cumulative conditional hazard on the interval [tj−1, tj) and, under the proportional hazards assumption,
it can be shown that
− log (1− λj(x)) = − log (1− λ0j) exp(β>x) (j ∈ J), (2.6)
where λ0j = 1 − exp
( − ∫ tjtj−1 λC0 (s) ds) is the associated cumulative baseline hazard on [tj−1, tj). Thus,
the cumulative hazard model (2.6) is directly connected with the discrete-time survival model (2.1) under
the complementary log transformation, and the two models have the same regression coefficient β.
3 Adaptive sampling design for optimal estimation
As introduced by Reilly and Pepe (1995) and Reilly (1996), we consider a sampling design that asymptoti-
cally minimizes the variance of parameter estimates of interest under constraints that the validation sample
size is fixed. In Theorem 1, we establish that the asymptotic variance of the mean score estimator depends
on the sampling probability for the phase two validation subset.
Theorem 1. For each j ∈ J , let αj = g(λ0j) ∈ R be transformation of baseline hazards in (2.1). Suppose
that the censoring time is bounded, that is P (C ≤ τ) = 1 for some fixed constant τ > 0, and that the
conditional hazard functions λj(x) = λ(tj |x) are bounded away from 0 and 1 for all x ∈ Rd. Under
the regularity conditions in Supplementary Material Section A.1, the mean score estimator θˆ of θ = (α,β)
solving the score equation of (2.4) is asymptotically normal such thatN1/2
(
θˆ−θ) d→ N(0,Σ) asN →∞,
where Σ = I−1V + I
−1
V ΩI
−1
V with IV = −E
[
∂2
∂θ∂θ> logL1(θ;Y,∆,X)
]
and Ω = E
[{pi(Y,∆,Z)−1 −
1}Var(U1(θ)|Y,∆,Z)] for the score function U1(θ) = ∂∂θ logL1(θ;Y,∆,X).
Suppose that we fix the sample probability for the validation subset by piV = E[pi(Y,∆,Z)], or empiri-
cally n/N . Then, the mean score estimator of θk, the k-th component of θ, is asymptotically efficient when
the validation sampling probability pi(Y,∆,Z) is proportional to
{
I−1V Var
(
U1(θ)|y, δ, z
)
I−1V
}1/2
[k,k]
, so that
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we empirically assign the optimal sampling size for each (y, δ, z)-stratum
nOpt(y, δ, z) ∝ N(y, δ, z)(I−1V Var(U1(θ)|y, δ, z)I−1V )1/2[k,k] (3.1)
satisfying n =
∑
(y,δ,z) n
Opt(y, δ, z), where M[j,k] denotes the (j, k)-element of a matrix M . We note
that (3.1) can be viewed as Neyman allocation (Neyman, 1934) maximizing the survey precision in the
stratified sampling based on the phase one information. Such an optimal design can be also obtained by the
Lagrangian multiplier method to minimize Σ[k,k] in Theorem 1, which equivalently minimizes the variance
of the target parameter θk with respect to pi(y, δ, z) under the constraint of a fixed-validation rate piV =
E[pi(Y,∆,Z)], or empirically n =
∑
(y,δ,z) pi(y, δ, z)N(y, δ, z).
Note that the optimal sampling design depends on external information about population structure,
namely IV and Var
(
U1(θ)|y, δ, z
)
, which are usually unknown. McIsaac and Cook (2015) introduced
an adaptive procedure for multi-phase analyses such that one first draws a pilot sample for validation
and then adaptively draws an additional validation set, write X PilotII,n = {(Yi,∆i,Xi) : i ∈ IPilot} and
XAdaptII,n = {(Yi,∆i,Xi) : i ∈ IAdapt}, respectively. That is, the overall validation XII,n = X PilotII,n ∪ XAdaptII,n
corresponds to the optimal design, where I = IPilot ∪ IAdapt. Similarly, we consider an adaptive con-
straint on the final validation size, n =
∑
(y,δ,z)
[
nPilot(y, δ, z) + nAdapt(y, δ, z)
]
, where nPilot(y, δ, z) and
nAdapt(y, δ, z) are sampling sizes on each (y, δ, z)-stratum for the pilot and adaptive validation, respectively.
We apply the Lagrangian multiplier method to minimize Σ[k,k] in Theorem 1 with respect to pi(Y,∆,Z)
under the adaptive constraint. Then, the adaptive sampling design is given by
nAdapt(y, δ, z) = nˆOpt(y, δ, z)− nPilot(y, δ, z), (3.2)
where nˆOpt(y, δ, z) is the estimated optimal sampling size of (3.1). Here, the information matrix IV and
the conditional variance of the score function Var
(
U1(θ)|y, δ, z
)
can be consistently estimated using the
individuals in the phase two pilot sample. We employ inverse probability weighting to estimate IV by
ÎV = − 1
N
∑
i∈IPilot
N(Yi,∆i,Zi)
nPilot(Yi,∆i,Zi)
∂2
∂θ∂θ>
logL1(θ;Yi,∆i,Xi). (3.3)
Also, Var
(
U1(θ)|y, δ, z
)
is estimated by the sample covariance matrix of the score function within each
(y, δ, z)-stratum such that
V̂ar
(
U1(θ)|y, δ, z
)
=
nPilot(y, δ, z)
nPilot(y, δ, z)− 1
{
µˆ2(θ; y, δ, z)− µˆ1(θ; y, δ, z)2
}
, (3.4)
where µˆ`(θ; y, δ, z) = nPilot(y, δ, z)−1
∑
i∈IPilot U1(θ;Yi,∆i,Xi)
` · I(Yi = y,∆i = δ,Zi = z), for ` = 1, 2.
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Then, we evaluate (3.3) and (3.4) with the inverse probability weighted estimator of θ based on the first
phase sample XI,N and the pilot validation set X PilotII,n . The expressions for the score function and Hessian
matrix of (2.3) for two discussed choices of the survival models can be found in Supplementary Material
Section A.2. Due to sparse observations or oversampled pilot data on some strata, we may not achieve
practically the optimal design with (3.2) when N(y, δ, z) < nˆOpt(y, δ, z) or nPilot(y, δ, z) > nˆOpt(y, δ, z). In
either case, we set nAdapt(y, δ, z) = 0∨{N(y, δ, z)−nPilot(y, δ, z)} for the saturated strata and distribute the
remaining validation allocation to the other strata proportional to the estimated optimal sampling sizes. This
approach for handling saturated strata is similar to that of McIsaac and Cook (2015), originally introduced
by Reilly and Pepe (1995).
4 Numerical illustrations
In this section, we examine the performance of our proposed mean score estimator and adaptive phase two
sampling procedure first by a computer simulation study. We then further illustrate the method with an
analysis of data from the National Wilms Tumor Study (NWTS). For this example, the original survival
outcome was continuous and so in addition to presenting the discrete time analysis, we consider whether
the proposed phase two sampling procedure provided efficiency gains for the analysis of the continuous
time outcome. We also provide further discussion on phase two sampling in the setting of intermittently
censored outcomes. Data and source code in R (version 3.6.1) for our numerical studies are provided at
https://github.com/kyungheehan/mean-score.
4.1 Simulation Study
Here, we evaluate the empirical performance of the proposed mean score estimator for the discrete survival
time setting via a simulation study. We also evaluate the degree to which the proposed adaptive validation
design improves estimation performance compared to simple random sampling and a balanced design for
several scenarios.
We consider the conditional hazard model (2.1) with the complementary log transformation g2(u) =
− log(1−u), where β = (log(1.5), log(0.7), log(1.3),− log(1.3))>. We assume survival status is observed
at discrete times 0 < t1 < t2 < · · · < t10 < ∞. As previously mentioned in Section 2.3, this model
will estimate the same β as in the underlying continuous-time Cox proportional hazards model. We first
generate a four dimensional covariate vector X = (X1, . . . , X4)>, which consists of both continuous and
binary variables.
We simulate correlated covariates with a unit scale between 0 and 1, by first considering a multivariate
normal random vector W = (W1, . . . ,W4)> with zero mean and Cov(Wj ,Wk) = 0.3|j−k|, so that we
9
l
l
l
l
l
l
l
l
l
l
2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time
λ(T
 
| X
)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Baseline
l
l
l
l
l
l
l
l
l
l
2 4 6 8 10
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Time
S(T
 
| X
)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Baseline
l
l
l
l
l
l
l
l
l
l
2 4 6 8 10
0.
05
0.
10
0.
15
0.
20
Time
P(T
 
| X
)
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
Baseline
Figure 1: Illustrations of the simulation setting for the discrete-time survival model. The conditional hazard function
(left) is demonstrated together with its associated survival and probability mass functions (middle and right), where
λ(tj |x) = P (T = tj |T ≥ tj ,X = x), S(tj |x) = P (T ≥ tj |X = x) and P (tj |x) = P (T = tj |X = x).
The baseline functions are illustrated in red and gray solid lines show realization of conditional hazards, survival and
probability functions associated with covariates for randomly chosen 100 subjects. The marginal rate of censoring
over the maximum follow-up period t6 is P (T > 6) ≈ 0.5.
put Xj = Qj(Φ(Wj)) for j = 1, 2 and Xj ∼ Bernoulli(Φ(Wj)) for j = 3, 4, where Φ is the cumulative
standard normal distribution function, and Q1 and Q2 are quantile functions of the beta distribution with
pairs of the shape and rate parameters (2, 1.5) and (3, 3), respectively. By doing this, all Xj’s are correlated
with each other, and particularly X1 and X2 are marginally beta random variables with Corr(X1, X2) ≈
0.290. Since continuous covariates are generally bounded in practice, the simulated continuous covariates
(X1, X2)
> represent standardized covariates over the range of observations into unit intervals.
For discrete survival outcomes, we note that P (T = tj |X = x) = λj(x)
∏j−1
k=1(1− λk(x)) enables us
to generate the discrete survival outcomes as multinomial random variables associated with covariates. To
simplify the censoring mechanism in our simulation, we set a fixed censoring time C = t6 as the maximum
follow-up for all subjects, so that we observe a truncated survival time Y = min{T, t6} and ∆ = I(T ≤ t6),
It is worth mentioning that the proposed method also allows a random censoring time C. An application of
the method with a more complex censoring mechanism will be considered in Section 4.2.
Next, we generate N -random copies XN = {(Yi,∆i,Xi) : 1 ≤ i ≤ N} of (Y,∆,X), which will
inform the benchmark full cohort analysis. We consider full cohort sizes N = 2000, 4000, 8000 in the
simulation. By choosing different baseline hazards, we considered three scenarios of overall censoring rates
with 30%, 50% and 70%. Here, we mainly refer to simulation results when the censoring rate is 50%,
since we found that this setting fundamentally provides similar lessons with the other scenarios which can
be found in the Supplementary Material Tables B.1 and B.2. Figure 1 illustrates the conditional hazard,
survival and probability functions in our simulation settings.
We assume that direct observations of X1 are not available in the phase one sample of the cohort, but
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instead one observes a discretized and error-prone exposure Z such that
Z =

1 (0 < X∗1 ≤ 0.25),
2 (0.25 < X∗1 ≤ 0.5),
3 (0.5 < X∗1 ≤ 0.75),
4 (0.75 < X∗1 < 1),
(4.1)
where X∗1 = X1 + ε is perturbation of X1 with an independent measurement error ε ∼ N(0, 0.12). Let
Zo be the true discretization of X1 defined similarly to Z by replacing X∗1 with X1. For the assumed
parameter values, the discordance or misclassified rate between Zo and Z was P (Zo 6= Z) ≈ 0.284 and
this shows that Z is not only a discrete but also an error-prone surrogate of X1, and potentially associated
with (X2, X3, X4). Finally, we set XI,N = {(Yi,∆i, Zi) : 1 ≤ i ≤ N} to be the phase one sample available
on all subjects.
Efficient estimation of the regression coefficient of X1 is of interest and the optimal sampling alloca-
tions are designed to minimize the variance of the β1 estimate in our simulation study. Since the optimal
sampling design (3.1) depends on nuisance parameters defined by the population structure, namely IV and
Var
(
U1(θ)|y, δ, z
)
in Theorem 1, we approximate their true values with empirical estimates obtained from
an externally generated large sample of size N0 = 104 that was independent from the full cohort XN . We
define the optimal sampling strategy based on these values as the oracle procedure and refer to Supplemen-
tary Material Section A.2 for some technical details for the derived optimal allocation. In practice, however,
the oracle procedure is infeasible and so we are interested in evaluating the adaptive sampling design as
described in Section 3. For this, we first sample a pilot validation subset X PilotII,n and estimate the optimal
sampling design together with the phase one sample XI,N . To accommodate all possible strata information
in the first phase sample, we employ balanced sampling for the pilot study, with nPilot(Yi,∆i, Zi) equal for
all {Yi,∆i, Zi}. We then estimate IV and Var
(
U1(θ)|y, δ, z
)
, as outlined at the end of the previous section.
Next, we draw an additional validation subset XAdaptII,n for each stratum following (3.2), and the mean score
method is finally applied to the two-stage analysis for the phase one sample XI,N and the adaptive phase two
sample XII,n = X PilotII,n ∪ XAdaptII,n . We considered validation subset sizes of n = 200, 400, 800 and took equal
proportions for the pilot and adaptive samples.
Due to saturated strata, there might be some remaining validation size to be allocated, for example
n/2−∑(y,δ,z) nPilot(y, δ, z) > 0 in the pilot study. In this case, we randomly select unvalidated subjects for
the remaining allocation, which is also similarly applied to the adaptive sample. We note that the proportion
of the pilot sample size to the adaptive entails a trade-off between precision of the nuisance parameters
needed for optimal sampling design and efficiency gains from the adaptive validation when the final phase
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two sample size is fixed. Some preliminary simulations showed that the adaptive sampling design with
nearly equal sizes of the pilot and adaptive samples usually produced robust and efficient estimates (data not
shown), which is similar to observations made by McIsaac and Cook (2015) for the two-stage analysis with
binary outcomes.
We compare our proposed adaptive sampling method, which we refer to here as mean score adaptive
(MS-A), to the mean score method using the oracle design (MS-O) and to some other standard estimation
methods for two-phase designs. The complete case analysis of fully randomly selected n-validation sample
(CC-SRS) will give unbiased results in likelihood-based inference. Since CC-SRS does not use auxiliary
information of the first stage sample, we examine if the optimal design for the mean score method improves
estimation performance of CC-SRS and evaluate efficiency gains from the two-stage analysis (MS-SRS). We
also conduct design-based estimation with balanced sampling such that validation size is equally allocated
to each (y, δ, z)-stratum of the first stage sample. Similarly to the proposed adaptive procedure, if there are
some remaining individuals to be allocated after balanced sampling, due to saturated strata, we randomly
sample the remaining from the unvalidated subjects to yield a final total phase two sample of n individuals.
The design-based estimation with balanced sampling is given by a Horvitz-Thompson type estimator (MS-
BAL), where sampling proportions of validation within strata are used for inverse probability weights as in
(2.4). For our setting, we note that the inverse probability weighted (IPW) estimator is technically the same
with the design-based mean score estimator which incorporates the balanced sampling weights pre-specified
in the two-phase analysis (McIsaac and Cook, 2014). We implement the proposed mean score estimator with
adaptive sampling described above, estimating the necessary nuisance parameters from the validation subset
(MS-A) and the when using the oracle design (MS-O). Finally, we consider the full cohort analysis (Full-
CC) based on fully observed data, as the benchmark performance, which empirically gives the upper bound
of efficiency for the two-phase analysis, since the Full-CC uses the complete covariate information on all
subjects.
We investigated two different aspects of varying sample sizes and conducted six simulation scenarios;
(i) increasing the phase two sample size from n = 200, 400, 800 with a fixed full cohort size N = 4000,
(ii) increasing the full cohort size from N = 2000, 4000, 8000 when the phase two sample size is fixed
by n = 200. Table 1 summarizes the relative performance for estimation of β1. Compared to CC-SRS,
MS-SRS had a reduction of the variance, which demonstrates efficiency gains of the mean score method
from employing auxiliary information of the phase one sample. For n = 400 and 800, MS-A was more
efficient than MS-SRS, whereas for n = 200, MS-SRS was more efficient. This suggests that n = 200 is
too small in this setting to gain efficiency using adaptive sampling; this is reasonable as the optimal sampling
allocation is based on estimates derived from a pilot sample half that size. MS-BAL had relatively inferior
performance compared to MS-SRS and MS-A, and this was true across all scenarios studied. The MS-O
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Table 1: Relative performance for the estimation of β1 is compared for (i) the complete case analysis with simple
random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-SRS), (iii) a design-
based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the mean score estimation
with adaptive sampling (MS-A) and the optimal sampling design (MS-O), for varying sample sizes. Results for the
full cohort estimator based on complete data are provided as a benchmark. Mean squared error (MSE) and its bias-
variance decomposition are estimated from 1000 Monte Carlo replications, where the censoring rate was 50%. The
adaptive and optimal sampling designs were for efficient estimation ofX1 with β1 = log(1.5) ≈ 0.405. In all adaptive
sampling scenarios, we took equal proportions for the pilot and adaptive samples.
Sampling Estimation Criterion
Estimation performance by sample sizes
N = 4000 n = 400
n = 200 n = 400 n = 800 N = 2000 N = 4000 N = 8000
Full cohort CC
√
MSE 0.094 0.094 0.094 0.129 0.094 0.067
Bias 0.003 0.003 0.003 0.004 0.003 0.000√
Var 0.094 0.094 0.094 0.129 0.094 0.067
SRS
CC
√
MSE 0.470 0.330 0.228 0.324 0.330 0.321
Bias 0.017 0.014 0.005 0.011 0.014 -0.010√
Var 0.470 0.329 0.228 0.324 0.329 0.321
MS
√
MSE 0.332 0.220 0.155 0.237 0.220 0.200
Bias 0.053 0.035 0.004 0.020 0.035 0.027√
Var 0.330 0.217 0.155 0.236 0.217 0.198
Balanced MS
√
MSE 0.400 0.278 0.194 0.276 0.278 0.265
Bias 0.042 0.024 0.010 0.026 0.024 0.021√
Var 0.398 0.277 0.194 0.275 0.277 0.264
Adaptive MS
√
MSE 0.374 0.197 0.147 0.214 0.197 0.190
Bias 0.049 0.007 0.006 0.004 0.007 0.002√
Var 0.371 0.197 0.147 0.214 0.197 0.189
Oracle MS
√
MSE 0.253 0.182 0.133 0.202 0.182 0.174
Bias 0.009 0.003 0.005 0.012 0.003 -0.005√
Var 0.252 0.182 0.133 0.202 0.182 0.174
had the smallest mean squared error (MSE) in all scenarios, as expected, and it turned out that the superior
performance of MS-O mostly came from variance reduction. As the cohort sample size increased, the
associated adaptive sampling design (MS-A) behaved closely to MS-O, which indicates that the proposed
adaptive approach consistently approximates the oracle procedure. In the scenarios studied, increasing the
phase two sample size was much more beneficial for efficiency gains for MS-A and MS-O, compared to the
sample size increment of the phase one study. For example, MS-A achieved 60.7%(≈ 1 − 0.147/0.374)
variance reduction while the validation rate increased four-fold from n = 200 to n = 800 given N = 4000
in the left three columns of Table 1. On the contrary, increasing the phase one sample size from N = 2000
to N = 8000 only produced 11.2%(≈ 1 − 0.190/0.214) improvement in the right three columns when
n = 400 is fixed. This suggests that the performance of the proposed MS-A procedure is sensitive to the
size of the phase two study, more so than the total cohort size for a fixed n.
Simulation results for all regression parameters and various combinations of n = 200, 400, 800 and
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N = 2000, 4000, 8000 can be found in Supplementary Material Tables B.3–B.7. Comparing the relative
performance of the methods for the other regression parameters, including those for the discrete baseline
hazards, we found that the MS-O outperformed the other estimators for all model parameters. The oracle
sampling design is infeasible in most practical situations; however, the two mean score estimators consis-
tently showed the best performance for the target parameter among all other practical competitors. MS-A
generally achieved the minimum mean squared errors for all parameters when the phase two sample size
exceeded 200, compared to the other practical estimators, for the scenarios studied (Supplementary Mate-
rial Tables B.3–B.7). For the setting where n = 200, the MS-SRS performed the best amongst the practical
estimators. These results suggest for that MS-A will perform well with respect to MSE for all model param-
eters, particularly the target and discrete proportional hazard parameters, for robust phase two sample size.
For small phase two samples and similar censoring rates, the MS-SRS may be preferred.
4.2 Data example: The National Wilms Tumor Study
Wilms tumor is a rare renal cancer occurring in children, where tumor histology and the disease stage at
diagnosis are two important risk factors for relapse and death. We consider data, reported by Kulich and
Lin (2004), on 3915 subjects from two randomized clinical trials from the National Wilms Tumor Study
(NWTS) (D’angio et al., 1989; Green et al., 1998). There are two measures of tumor histology, which
is classified as either favorable (FH) or unfavorable (UH), one by a local pathologist and the other by an
expert pathologist from a central facility. Because of the rarity of disease, local pathologists may be less
familiar with Wilms Tumor and their assessment is subject to misclassification. The central assessment is
considered to be the gold standard, or true histology in our analysis, and the local evaluations are considered
surrogate observations for the central evaluation. Since histology for all subjects was validated by the
central laboratory, NWTS data has been widely used to evaluate two-phase sampling methodology, such as
by Breslow and Chatterjee (1999), Kulich and Lin (2004) and Lumley (2011).
We demonstrate our proposed mean score method for discrete-time survival in an analysis of relapse in
this NWTS cohort. We assume that the local histology is available for all subjects in a first phase sample
and that only a sub-cohort was sampled for evaluation by the central pathologist in a second phase sample.
Specifically, we are interested in the proportional hazards discrete-time survival model (2.1) for time to
relapse, under the complementary log transformation g2(u) = − log(1 − u), in order to evaluate the risk
associated with unfavorable central histology, late (III/IV) disease stage versus the early (I/II) stage, age at
diagnosis (year), and tumor diameter (cm). For this model, we also include an interaction between histology
and stage of disease.
In this cohort, 90% of the 669 events occurred within the first three years of diagnosis, while less than
5% of non-relapsed subjects were censored in the same period. Based on this observation, we first define a
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modified, or reduced, cohort to include only patients who had an event or were fully followed up in the first
3 years, so that censoring only occurs at the third year (82.2%), the assumed end of the study. This modified
cohort included N = 3757 subjects and is used in our NWTS data analysis. We consider the regression
coefficients from the discrete-time survival analysis of the modified full cohort as the reference values. We
took this approach first out of concern that the large number of nuisance parameters introduced by the small
number of individuals with intermittent censored outcomes, due to the added strata for a binary outcome
at each failure time interval, might adversely affect the mean score method. We will evaluate efficiency
gains of the optimal mean score design, based on the discretized survival outcomes, for the continuous-time
analysis in Section 4.3. Finally, we also conducted an analysis of all individuals, regardless of the time of
censoring, and discuss design issues regarding how to handle intermittent censoring in our framework in
Section 4.4.
We first discretize the continuous event time into six 6-month intervals, so that we model the hazard of
relapse during the first three years after diagnosis. As in Section 4.1, we consider four different sampling
scenarios for the phase two subsample: simple random sampling, balanced allocation across strata, the
adaptive and optimal (oracle) mean score designs, where the last three employ stratified sampling based on
the phase one sample. To evaluate the efficiency gains of the proposed mean score approach, we performed
the two-stage analysis, with a phase two sample of n = 400, 1000 times. For implementation of the optimal
design, we estimate parameters in (3.1) using the oracle procedure by using the central histology records
of the full cohort. We refer to Section 4.1 for further details of implementation. Bias and efficiency are
calculated using the estimates of the full cohort analysis with the central histology as the reference.
Table 2 demonstrates the performance of the different methods, where efficient estimation of the in-
teraction between unfavorable histology and late stage of the disease is of main interest. MS-A out-
performed the other practical competitors: CC-SRS, MS-SRS and MS-BAL. For example, MS-A had a
38.7%(≈ 1 − 0.425/0.693) variance reduction compared to CC-SRS for estimating the interaction term.
We also note that performance of MS-A was pretty close to the oracle procedure, MS-O; MS-A was only
7% less efficient than MS-O for estimating the regression coefficient of interest. Furthermore, across all
parameters, MS-A achieved the smallest mean squared error among the practical competitors, not only for
baseline hazards estimation but also regression coefficients. Overall, the proposed method performed better
than the other two-phase estimators, with both an efficient design and by incorporating auxiliary information
from the phase one sample.
In Figure 2, we examine the relative performance of the different estimators for each of the regression
parameters and phase two sample sizes n = 200, 400, 800. In the top-left panel (a), we show the estimation
results for the regression coefficient for unfavorable histology (UH) over 1000 repetitions of subsampling,
when the adaptive and optimal mean score allocations were designed for the efficient estimation of UH. The
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Table 2: For the discrete-time survival analysis of the National Wilms Tumor Study, we compare five different meth-
ods: (i) Complete case analysis with simple random sampling (CC-SRS), (ii) mean score estimation with simple
random sampling (MS-SRS), (iii) mean score estimation with a balanced sample (MS-BAL), also equivalent to the
Horvitz-Thompson estimator, (iv) mean score estimation with adaptive sampling (MS-A) and (v) mean score estima-
tion with the optimal sampling design (MS-O). The optimal sampling design was estimated using the full cohort data.
The MS-A and MS-O designs are for efficient estimation of the interaction effect between unfavorable histology and
disease stage. Results from the full cohort analysis with complete data are presented as a benchmark. Mean squared
error and its bias-variance decomposition are estimated using 1000 phase two samples of n = 400 from the reduced
full cohort (N = 3757). We took equal proportions for the pilot and adaptive samples.
Sampling Estimation Criterion Baseline hazard in complementary log-log scale Regression coefficient0.5yr 1yr 1.5yr 2yr 2.5yr 3yr UH1 Stage2 Age3 dTmr4 U∗S5
Full cohort CC Estimate -4.028 -3.876 -4.336 -5.005 -5.353 -5.719 1.058 0.280 0.063 0.032 0.636
SRS
CC
√
MSE 0.452 0.456 0.458 0.666 1.459 2.468 0.555 0.317 0.046 0.031 0.693
Bias -0.071 -0.065 -0.077 -0.096 -0.278 -0.649 -0.015 0.018 -0.002 0.001 0.032√
Var 0.446 0.451 0.452 0.659 1.432 2.381 0.555 0.317 0.046 0.031 0.692
MS
√
MSE 0.420 0.414 0.411 0.558 1.375 2.441 0.548 0.337 0.047 0.034 0.732
Bias -0.041 -0.034 -0.042 -0.101 -0.291 -0.757 -0.091 0.017 -0.001 0.002 0.094√
Var 0.418 0.412 0.409 0.549 1.344 2.320 0.541 0.337 0.047 0.034 0.726
Balanced MS
√
MSE 0.410 0.404 0.396 0.391 0.389 0.388 0.370 0.353 0.056 0.035 0.554
Bias -0.109 -0.096 -0.084 -0.076 -0.072 -0.070 0.043 0.007 0.013 0.005 0.004√
Var 0.396 0.393 0.387 0.383 0.382 0.382 0.368 0.353 0.054 0.035 0.554
Adaptive MS
√
MSE 0.315 0.309 0.303 0.299 0.297 0.296 0.284 0.254 0.042 0.025 0.425
Bias -0.065 -0.058 -0.052 -0.048 -0.046 -0.045 0.003 -0.007 0.008 0.003 0.034√
Var 0.308 0.304 0.298 0.295 0.294 0.293 0.284 0.254 0.041 0.025 0.424
Oracle MS
√
MSE 0.311 0.306 0.301 0.296 0.299 0.295 0.250 0.256 0.038 0.025 0.396
Bias -0.048 -0.043 -0.038 -0.035 -0.042 -0.036 0.010 0.003 0.004 0.001 0.013√
Var 0.307 0.303 0.298 0.294 0.296 0.293 0.250 0.256 0.037 0.025 0.396
1 Unfavorable histology versus favorable; 2 disease stage III/IV versus I/II;
3 year at diagnosis; 4 tumor diameter (cm); 5 interaction effect between UH and Stage.
rest of the panels are similar, showing results for the other regression coefficients they were set as targets,
namely when the MS-A and MS-O designs were for efficient estimation of (b) late stage of the disease, (c)
age of diagnosis (year), (d) tumor diameter (cm) and (e) the interaction between UH and stage of the disease,
respectively. MS-O consistently showed superior performance for all phase two ample sizes; however, MS-
A again had the smallest mean squared error among the practical methods. Further, the performance of
MS-A tended to be close to MS-O as the validation size increased.
4.3 Continuous-time survival analysis with the mean score design
In many practical settings, the continuous-time Cox model will be the analysis of primary interest. We
further investigate benefits of the proposed mean score sampling design, when the phase two estimating
equation employs the continuous-time Cox proportional hazards model. In Section 2.3, we discussed the
direct connection between the the continuous-time Cox model (2.1) and the analogous grouped discrete-time
model with the complementary log transformation, in the sense that the two models have the same regression
coefficient β. We can conduct the two-phase analysis of the Cox model with the proposed optimal mean
score sampling method derived for the parameter of interest in the discretized model.
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(a) Unfavorable histology (UH) (b) Late stage of disease
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Figure 2: We demonstrate the relative performance of different methods by repeatedly subsampling the phase two
sample 1000 times from the reduced full cohort (N = 3757) of the National Wilms Tumor Study data, while varying
the target parameter for efficient estimation and the phase two sample size. Efficient results are shown for (a) unfavor-
able histology, (b) late stage of the disease, (c) age of diagnosis (year), (d) tumor diameter (cm), and the interaction
between the histology and late stage, respectively, when validation sizes are n = 200, 400, 800. The yellow horizontal
lines represent the reference parameter estimates obtained from the full cohort analysis.
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Table 3 demonstrates performance comparison of different sampling methods when they were applied
to the two-phase analysis of the usual Cox model based on 1000 repeated phase two samples in the NWTS
data. Unlike the previous analysis in Table 2 or Figure 2, we assumed that the continuous relapse times
were observed for the full cohort in the phase one study and employed the previously developed optimal
and adaptive mean score design for the discrete-time survival model (2.1) only to design the allocation
of the phase two sample. That is, we first calculated the sampling probabilities and associated inverse
probability weights for the phase two sample, and then the design-based estimates of the continuous-time
Cox model were reported in Table 3. We assumed efficient estimation of the interaction effect between
unfavorable histology and disease stage was of primary interest in the adaptive and oracle sampling designs.
We used the survival package in R (Therneau and Lumley, 2019) and applied the inverse probability
weights of the phase two sample with the weights option of the coxph function. As shown in Table 3, the
adaptive sampling design for the discrete-time analysis also provided efficiency gains for the continuous-
time analysis. For example, the variance reduction was about 26% compared to both the simple random
sampling and the balanced design. In this example, the adaptive design happened to slightly outperform the
Table 3: Performance the two-phase continuous-time Cox model analysis of time to relapse in the National Wilms
Tumor Study. We used inverse probability weights (IPW) for the two-phase analysis for four different sampling
designs for the second phase; (i) simple random sampling (SRS), (ii) balanced sampling, (iii & iv) the proposed
adaptive and oracle sampling designs, respectively, determined by the mean score method for the discrete-time survival
analysis. We took equal proportions for the pilot and adaptive samples. The target parameter for the mean score design
was the interaction between unfavorable histology and late stage disease. Mean squared error and its bias-variance
decomposition are estimated from 1000 phase two subsamples of n = 400 from the reduced full cohort (N = 3757).
Reference parameters estimates are from the full cohort analysis using the continuous-time Cox model with complete
data on all subjects.
Sampling Criterion Estimation performance by regressorUH1 Stage2 Age3 dTmr4 U∗S5
Full cohort analysis Ref. 1.027 0.292 0.064 0.022 0.620
SRS
√
MSE 0.388 0.313 0.046 0.033 0.600
Bias -0.018 0.014 -0.002 0.001 0.028√
Var 0.387 0.312 0.046 0.033 0.599
Balanced
√
MSE 0.413 0.421 0.061 0.043 0.622
Bias 0.057 0.020 0.010 0.006 -0.008√
Var 0.409 0.420 0.060 0.042 0.622
Adaptive
√
MSE 0.308 0.297 0.048 0.030 0.461
Bias -0.000 -0.006 0.007 0.003 0.039√
Var 0.308 0.296 0.048 0.029 0.459
Oracle
√
MSE 0.313 0.332 0.046 0.031 0.477
Bias -0.001 0.001 0.000 0.000 0.035√
Var 0.313 0.332 0.046 0.031 0.476
1 Unfavorable histology versus favorable; 2 disease stage III/IV versus I/II;
3 year at diagnosis; 4 tumor diameter (cm); 5 interaction effect between UH and Stage.
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oracle one, but we note that these two allocations were for the optimal design for the discrete-time and not
the continuous survival model (2.1). We found that the proposed adaptive sampling design provided 20%–
25% of efficiency gains in each case varying the target parameter to be (a) unfavorable histology (UH), (b)
late stage of the disease, (c) age of diagnosis (year) or (d) tumor diameter (cm) (data not shown).
4.4 Design considerations for general censoring patterns
The proposed method in Section 3 can be applied without modification for the setting where there is random
intermittent censoring, as well as censoring at the end of the study; the only difference being that there will be
more strata at the intermittent event times. The mean score estimation depends on nonparametric estimation
of the probability distribution for the phase two variables conditional on each discrete value of the phase one
surrogate. We note that pˆi(Yi,∆i,Zi) in Section 2.2 is the empirical estimate of the sampling probability
of the i-th individual selected into the validation subset, which may suffer from the curse of dimensionality
as the number of phase one strata (Yi,∆i,Zi) increases. One could consider an increasing number of
discretized intervals to approximate the continuous-time points, but the number of unique continuous-time
survival outcomes observed will increase as the sample size increases. For this reason, in our data example
we first studied the two-phase analyses of the discrete-time survival models in the previous sections where
individuals were right-censored only at the sixth time point, an induced end of follow-up, which is equivalent
to a fixed Type I censoring when individuals who were intermittently censored were excluded from analysis.
Even in this simple setting in Section 4.1, there were (7 × 4)-strata for the phase two sampling, resulting
from a discrete surrogate Z having four categories. If we further considered random right-censoring for
this setting, we would have to estimate sampling probabilities for (6 × 2 × 4)-strata. The larger number
of associated nuisance parameters in this case for MS-A estimator may require larger phase two samples to
achieve the expected efficiency gains due to unstable nuisance parameter estimation in small strata. Indeed,
in our simulation study with Type I censoring only, we saw that when n = 200, the MS-A did not outperform
MS-SRS.
We suggest a simple strategy for the proposed adaptive mean score design aimed at under-sampling less
informative strata in the pilot study, which may preserve efficiency gains by providing more precise nuisance
parameters for the more informative strata. For example, under the random right-censoring assumption,
individuals censored before the end of the follow-up period should generally be be less informative than
a non-censored individuals with similar covariates for that same period. For a fixed phase two sample
size, such under-sampling may enable us to re-allocate the pilot sample for the MS-A so that relatively
more informative groups can be up-weighted. In fact, we anticipate that the optimal adaptive design would
allocate very few individuals in these strata, so we seek to avoid putting too many individuals into these
strata in the pilot. Supplementary Material Tables B.8 and B.9 provide analogous results for the discrete-
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time analysis in Table 2 and continuous time analysis of Table 3 for the NWTS, but we analyzed the full
cohort (N = 3915) and under-sampled the censored individuals not relapsing before the end of the follow-
up period in the balanced and the pilot samples. Specifically, we allocated a small number of the pilot
sample size for individuals censored before the end of the follow-up period (i.e., y < 3 and δ = 0) at
each level of histology, and the remaining allocation was equally distributed to the other strata in the pilot
sample. In this particular example, we set the under-sampling size to 4, which was approximately half
of the balanced sampling size for each stratum in the pilot study with n = 400. Indeed, we found that
the naive balanced sampling of all strata in the pilot often over-sampled censored-groups compared to the
oracle design (data not shown), and consequently this simple remedy made the modified adaptive sampling
design be closer to the oracle design than did the balanced pilot sample with the proposed adaptive design.
As seen in Supplemental Table B.8, the modified approach produced a 14% variance reduction compared
to both the fully balanced and the MS-A with a balanced pilot sample. Additionally, the precision for all
estimates, relative to the analogous estimates in Tables 2 and 3, benefited from including the intermittently
censored 158 (= 3915 − 3757) individuals who had been excluded in Section 4.2, with more gains seen
for the MS-BAL and MS-A estimators. We hypothesize that this modification will allow for more robust
efficiency gains for the proposed adaptive design in other settings with intermittent censoring. Supportive
simulation studies that examine the performance of MS-A given the anticipated phase two sample size and
other study parameters may provide useful insights to guide refinements of this strategy for a given setting.
5 Discussion
The mean score method is a practical approach for two-phase studies that allows for a relatively straightfor-
ward derivation of an optimal design for a phase two study, one that can minimize the variance of a target
parameter given a fixed phase two sample size (Reilly and Pepe, 1995). In this study, we extended the mean
score estimation method for the two-phase analysis of discrete-time survival outcomes. We also derived an
adaptive sampling design approach that first draws a pilot phase two sample in order to estimate the nuisance
parameters necessary to derive the optimal sampling proportions, similar to the approach of McIsaac and
Cook (2015) for binary outcomes.
Through numerical studies with simulated data and the National Wilms Tumor Study data, we found
that the proposed mean score estimator with an adaptive sampling design provided efficiency gains over
the complete case estimator, as well as the mean score estimator with simple random or balanced stratified
sampling, for selection of the phase two sample. For the studied settings, as the phase two sample size
increased, the proposed adaptive sampling design not only outperformed the simple random sampling and
balanced designs consistently but also behaved very close to the oracle design, which depends on the true
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(generally unknown) population parameters.
The mean score adaptive optimal design also provided efficiency gains for the two-phase analysis of the
continuous-time outcome using the usual Cox proportional hazards model. This design offers a practical and
straightforward approach two improve the efficiency of the two-phase estimator for the continuous survival
time setting and can be applied for settings with both type I and random right censoring.
There are some limitations of our proposed method. The adaptive design requires estimating nuisance
parameters to estimate the strata-specific sampling probabilities that minimize the variance of the target
parameter, whose number increases with the number of strata. Many small strata could lead to instability
in the necessary estimated nuisance parameters, which in turn could threaten the efficiency of the design.
For continuous surrogates, a kernel smoothing approach proposed by Chatterjee and Chen (2007) may be
useful. In the case of the Wilms Tumor data, undersampling the early censored individuals in the pilot was an
advantageous approach that was compatible with the subsequent derived optimal sample, in that it avoided
oversampling uninformative strata, and improved the performance of the adaptive design. Formalization
of this strategy needs further study and is a subject for future work. Incorporation of prior information
regarding the sampling priorities for certain strata may be an additional way to improve the performance
of the adaptive design, particularly in the case of a small phase two sample. Chen et al. (2019) considers a
method for incorporation of prior information into multi-wave sampling in a regression framework.
Two-phase studies are used in a variety of settings. In the era where the analysis of error-prone electronic
health records data are of increasing interest, a phase two sample in which data can be validated to under-
stand the error structure is a critical step towards valid inference. The proposed method and two-phase study
design offer a practical and easy to implement framework for the common setting of survival outcomes, in
which both the validated and error-prone exposures can be efficiently combined so that analyses are adjusted
for errors in the surrogate data. Future work is needed to expand this method to also handle settings where
there is error in both the exposure and survival outcome.
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A Technical details
A.1 Regularity conditions for Theorem 1
We assume there exists J ≥ 1 such that P (Y ≤ tJ) with probability one. Let θ0 ∈ Θ0 be the true parameter
for some open Θ0 ⊂ RJ+d and further assume the following conditions:
A1. E|L1(θ;Y,∆,X)| <∞ at θ0.
A2. L1(θ;Y,∆,X) is three-times continuously differentiable and bounded away from 0 near θ0 (a.s.).
A3. IV = −E
[
∂2
∂θ∂θ> logL1(θ;Y,∆,X)
]
is positive definite at θ0.
A4. pi(y, δ, z) > 0 for all (y, δ, z).
Since we have formulated discrete-time survival models where the censoring time C is bounded away from
infinity, the right-censored survival time Y has an upper-bound tJ almost surely so that finite numbers
of baseline hazards suffice to specify likelihood for the discrete-time survival model (2.1). Without loss
of generality, we write α = (α1, . . . , αJ)> by the transformation of baseline hazards. Then, the above as-
sumptions A1–A4 are the regularity conditions for the maximum likelihood estimation of finite-dimensional
parameters θ = (α,β), and therefore, the proof follows Theorem 1 in Reilly and Pepe (1995) which we
refer the reader to for details.
A.2 Some derivations for numerical implementation
For the implementation of the optimal design in our numerical simulations, we empirically estimated certain
parameters by generating a large independent sample of N0 individuals. Let X ?N0 = {(Y ?i ,∆?i ,X?i ,Z?i ) :
1 ≤ i ≤ N0} be an external random sample of (Y,∆,X,Z) independent on XN or XI,N . We estimate
1
unknown quantities in the optimal sampling design (3.1) by
Î?V = −
1
N0
N0∑
i=1
∂2
∂θ∂θ>
logL1(θ;Y
?
i ,∆
?
i ,X
?
i ),
V̂ar
?(
U1(θ)|y, δ, z
)
=
N?(y, δ, z)
N?(y, δ, z)− 1
{
µˆ?2(θ; y, δ, z)− µˆ?1(θ; y, δ, z)2
}
,
(A.1)
where N?(y, δ, z) =
∑N0
i=1 I(Y ?i = y,∆?i = δ,Z?i = z) and
µˆ?` (θ; y, δ, z) =
1
N?(y, δ, z)
N0∑
i=1
U1(θ;Y
?
i ,∆
?
i ,X
?
i )
` · I(Y ?i = y,∆?i = δ,Z?i = z) (A.2)
for ` = 1, 2.
We now introduce some derivations for Newton-Raphson algorithm. Recall that the discrete-time sur-
vival model (2.1) under the odds transformation g1(u) = u1−u is given by logit(λj(x)) = αj + β
>x, where
αj = logit(λ0j) is the logit transformation of the baseline hazard. The maximum likelihood estimates of α
and β are obtained by solving score equations of (2.4) with
∂
∂αj
QN (α,β) =
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i))
(
Dij − e
αj+β
>Xi
1 + eαj+β
>Xi
)
= 0,
∂
∂β
QN (α,β) =
∑
i∈I
pˆi(Yi,∆i,Zi)
−1
J(i)∑
j=1
(
Dij − e
αj+β
>Xi
1 + eαj+β
>Xi
)
Xi = 0.
(A.3)
We numerically solve the system of equations (A.3) with the Newton-Raphson algorithm using the associ-
ated Hessian matrix whose components consist of
∂2
∂αj∂αj′
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i)) e
αj+β
>Xi(
1 + eαj+β
>Xi
)2 I(j = j′),
∂2
∂αj∂β
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i)) e
αj+β
>Xi(
1 + eαj+β
>Xi
)2 Xi,
∂2
∂β∂β>
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1
J(i)∑
j=1
eαj+β
>Xi(
1 + eαj+β
>Xi
)2 XiX>i .
(A.4)
Similarly, suppose the complementary log transformation g2(u) = − log(1 − u) defines the true sur-
vival model (2.1). Then it can be easily seen that logit(λj(x)) = exp
(
eαj+β
>x) − 1, where αj =
log(− log(1 − λ0j)) is the complementary log-log transformation of the baseline hazard. The maximum
2
likelihood estimates of θ = (α,β) are obtained by solving score equations of (2.4) with
∂
∂αj
QN (α,β) =
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i))
(
Dij
eαj+β
>Xi
1− eexp(αj+β>Xi)
− eαj+β>Xi
)
= 0,
∂
∂β
QN (α,β) =
∑
i∈I
pˆi(Yi,∆i,Zi)
−1
J(i)∑
j=1
(
Dij
eαj+β
>Xi
1− eexp(αj+β>Xi)
− eαj+β>Xi
)
Xi = 0.
(A.5)
We numerically solve the system of equations (A.5) with the Newton-Raphson algorithm using the associ-
ated Hessian matrix whose components consist of
∂2
∂αj∂αj′
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i))
{
Dij
eαj+β
>Xi
1− eexp(αj+β>Xi)
×
(
1− e
αj+β
>Xie− exp(αj+β
>Xi)
1− eexp(αj+β>Xi)
)
− eαj+β>Xi
}
I(j = j′),
∂2
∂αj∂β
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1I(j ≤ J(i))
{
Dij
eαj+β
>Xi
1− eexp(αj+β>Xi)
×
(
1− e
αj+β
>Xie− exp(αj+β
>Xi)
1− eexp(αj+β>Xi)
)
− eαj+β>Xi
}
Xi,
∂2
∂β∂β>
QN (α,β) = −
∑
i∈I
pˆi(Yi,∆i,Zi)
−1
J(i)∑
j=1
{
Dij
eαj+β
>Xi
1− eexp(αj+β>Xi)
×
(
1− e
αj+β
>Xie− exp(αj+β
>Xi)
1− eexp(αj+β>Xi)
)
− eαj+β>Xi
}
XiX
>
i .
(A.6)
3
B Additional numerical results
B.1 Supplemental tables for the simulation study
Table B.1: Relative performance for the estimation of β1 is compared for (i) the complete case analysis with simple
random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-SRS), (iii) a design-
based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the mean score estimation
with adaptive sampling (MS-A) and the optimal sampling design (MS-O), for varying sample sizes. Results for the full
cohort estimator based on complete data are provided as a benchmark. Mean squared error (MSE) and its bias-variance
decomposition are estimated from 1000 Monte Carlo replications, where the censoring rate was 30%. The adaptive
and optimal sampling designs were for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405. In all scenarios, we
took equal proportions for the pilot and adaptive samples.
Sampling Estimation Criterion
Estimation performance by sample sizes
N = 4000 n = 400
n = 200 n = 400 n = 800 N = 2000 N = 4000 N = 8000
Full cohort CC
√
MSE 0.079 0.079 0.079 0.112 0.079 0.056
Bias 0.004 0.004 0.004 0.000 0.004 0.001√
Var 0.079 0.079 0.079 0.112 0.079 0.056
SRS
CC
√
MSE 0.408 0.284 0.198 0.281 0.284 0.282
Bias 0.013 0.012 0.011 0.013 0.012 0.015√
Var 0.408 0.284 0.197 0.281 0.284 0.282
MS
√
MSE 0.268 0.177 0.132 0.191 0.177 0.170
Bias 0.067 0.016 0.012 0.014 0.016 0.017√
Var 0.259 0.176 0.131 0.190 0.176 0.169
Balanced MS
√
MSE 0.302 0.216 0.153 0.219 0.216 0.202
Bias 0.023 0.017 0.015 0.010 0.017 0.018√
Var 0.301 0.215 0.152 0.219 0.215 0.201
Adaptive MS
√
MSE 0.279 0.168 0.114 0.181 0.168 0.159
Bias 0.038 0.024 0.011 0.012 0.024 0.017√
Var 0.276 0.166 0.113 0.181 0.166 0.158
Oracle MS
√
MSE 0.213 0.155 0.112 0.166 0.155 0.137
Bias 0.025 0.001 0.001 0.005 0.001 0.002√
Var 0.212 0.155 0.112 0.166 0.155 0.137
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Table B.2: Relative performance for the estimation of β1 is compared for (i) the complete case analysis with simple
random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-SRS), (iii) a design-
based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the mean score estimation
with adaptive sampling (MS-A) and the optimal sampling design (MS-O), for varying sample sizes. Results for the full
cohort estimator based on complete data are provided as a benchmark. Mean squared error (MSE) and its bias-variance
decomposition are estimated from 1000 Monte Carlo replications, where the censoring rate was 70%. The adaptive
and optimal sampling designs were for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405. In all scenarios, we
took equal proportions for the pilot and adaptive samples.
Sampling Estimation Criterion
Estimation performance by sample sizes
N = 4000 n = 400
n = 200 n = 400 n = 800 N = 2000 N = 4000 N = 8000
Full cohort CC
√
MSE 0.119 0.119 0.119 0.175 0.119 0.086
Bias 0.000 0.000 0.000 0.004 0.000 0.003√
Var 0.119 0.119 0.119 0.175 0.119 0.086
SRS
CC
√
MSE 0.630 0.420 0.299 0.442 0.420 0.419
Bias 0.025 0.016 0.002 -0.005 0.016 0.018√
Var 0.630 0.420 0.299 0.442 0.420 0.418
MS
√
MSE 0.477 0.304 0.208 0.328 0.304 0.287
Bias 0.177 0.078 0.018 0.065 0.078 0.081√
Var 0.443 0.294 0.207 0.322 0.294 0.273
Balanced MS
√
MSE 0.535 0.330 0.225 0.347 0.330 0.327
Bias 0.092 0.026 0.005 0.033 0.026 0.029√
Var 0.527 0.329 0.224 0.346 0.329 0.326
Adaptive MS
√
MSE 0.411 0.250 0.178 0.259 0.250 0.225
Bias 0.018 0.007 0.001 0.003 0.007 0.003√
Var 0.410 0.250 0.178 0.259 0.250 0.225
Oracle MS
√
MSE 0.315 0.215 0.174 0.250 0.215 0.224
Bias 0.023 0.010 0.000 0.017 0.010 0.008√
Var 0.314 0.214 0.174 0.249 0.214 0.224
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Table B.3: Relative performance for the estimation of regression parameters is compared for (i) the complete case
analysis with simple random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-
SRS), (iii) a design-based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the
mean score estimation with adaptive sampling (MS-A) and the optimal sampling design (MS-O), where n = 200
subsample was drawn from the full cohort size of N = 4000. Results for the full cohort estimator based on complete
data are provided as a benchmark. Mean squared error (MSE) and its bias-variance decomposition are estimated from
1000 Monte Carlo replications, where the censoring rate was 50%. The adaptive and optimal sampling designs were
for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405.
Sample size Sampling Estimation Criterion Estimation performance by regression coefficient
α1 α2 α3 α4 α5 α6 β1 β2 β3 β4
n = 200
SRS
CC
√
MSE 0.547 0.520 0.447 0.429 0.409 0.396 0.470 0.555 0.214 0.203
Bias -0.086 -0.076 -0.064 -0.034 -0.033 -0.008 0.017 -0.017 0.013 -0.009√
Var 0.540 0.514 0.443 0.428 0.408 0.396 0.470 0.555 0.214 0.202
N = 4000
MS
√
MSE 0.479 0.381 0.330 0.316 0.306 0.301 0.332 0.602 0.236 0.219
Bias -0.267 -0.166 -0.112 -0.086 -0.074 -0.056 0.053 -0.021 0.020 -0.017√
Var 0.398 0.343 0.310 0.304 0.297 0.295 0.330 0.601 0.235 0.218
Balanced MS
√
MSE 0.405 0.401 0.399 0.398 0.398 0.405 0.400 0.859 0.317 0.299
Bias -0.023 -0.011 -0.009 -0.002 0.009 0.034 0.042 -0.034 0.025 -0.017√
Var 0.404 0.400 0.399 0.398 0.398 0.403 0.398 0.858 0.317 0.298
Adaptive MS
√
MSE 0.332 0.324 0.323 0.323 0.325 0.326 0.374 0.720 0.255 0.251
Bias -0.018 -0.007 -0.006 -0.001 0.006 0.024 0.049 -0.065 0.025 -0.028√
Var 0.331 0.324 0.323 0.323 0.325 0.325 0.371 0.717 0.254 0.249
Oracle MS
√
MSE 0.258 0.253 0.255 0.252 0.251 0.254 0.253 0.519 0.198 0.189
Bias -0.013 0.003 0.002 0.005 0.007 0.018 0.009 -0.027 0.001 -0.017√
Var 0.257 0.253 0.255 0.252 0.251 0.253 0.252 0.518 0.198 0.188
Full cohort analysis
√
MSE 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
Bias -0.010 0.000 -0.003 -0.002 -0.005 -0.002 0.003 -0.001 -0.000 0.000√
Var 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
(α1, α2, α3, α4, α5, α6) = (−3.410,−3.027,−2.641,−2.249,−1.849,−1.435);
(β1, β2, β3, β4) = (log(1.5), log(0.7), log(1.3),− log(1.3)) ≈ (0.405,−0.357, 0.262,−0.262).
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Table B.4: Relative performance for the estimation of regression parameters is compared for (i) the complete case
analysis with simple random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-
SRS), (iii) a design-based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the
mean score estimation with adaptive sampling (MS-A) and the optimal sampling design (MS-O), where n = 400
subsample was drawn from the full cohort size of N = 4000. Results for the full cohort estimator based on complete
data are provided as a benchmark. Mean squared error (MSE) and its bias-variance decomposition are estimated from
1000 Monte Carlo replications, where the censoring rate was 50%. The adaptive and optimal sampling designs were
for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405.
Sample size Sampling Estimation Criterion Estimation performance by regression coefficient
α1 α2 α3 α4 α5 α6 β1 β2 β3 β4
n = 400
SRS
CC
√
MSE 0.377 0.347 0.319 0.295 0.288 0.280 0.330 0.404 0.146 0.143
Bias -0.050 -0.045 -0.037 -0.014 -0.025 -0.008 0.014 0.000 0.006 -0.004√
Var 0.374 0.344 0.316 0.295 0.287 0.280 0.329 0.404 0.146 0.143
N = 4000
MS
√
MSE 0.253 0.226 0.216 0.209 0.204 0.203 0.220 0.423 0.154 0.147
Bias -0.081 -0.046 -0.039 -0.032 -0.030 -0.022 0.035 0.005 0.007 -0.005√
Var 0.240 0.222 0.213 0.207 0.202 0.202 0.217 0.423 0.154 0.147
Balanced MS
√
MSE 0.284 0.279 0.276 0.276 0.277 0.277 0.278 0.582 0.200 0.204
Bias -0.014 -0.003 -0.004 -0.000 0.003 0.016 0.024 -0.007 0.006 -0.015√
Var 0.284 0.279 0.276 0.276 0.277 0.277 0.277 0.582 0.200 0.204
Adaptive MS
√
MSE 0.210 0.200 0.201 0.201 0.198 0.201 0.197 0.426 0.147 0.147
Bias -0.013 -0.003 -0.005 -0.003 -0.002 0.005 0.007 -0.014 0.006 -0.009√
Var 0.210 0.200 0.200 0.201 0.198 0.200 0.197 0.426 0.147 0.147
Oracle MS
√
MSE 0.189 0.184 0.182 0.177 0.178 0.178 0.182 0.354 0.134 0.132
Bias -0.003 0.007 0.005 0.006 0.005 0.011 0.003 -0.014 -0.005 -0.008√
Var 0.189 0.184 0.182 0.177 0.178 0.177 0.182 0.354 0.133 0.132
Full cohort analysis
√
MSE 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
Bias -0.010 0.000 -0.003 -0.002 -0.005 -0.002 0.003 -0.001 -0.000 0.000√
Var 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
(α1, α2, α3, α4, α5, α6) = (−3.410,−3.027,−2.641,−2.249,−1.849,−1.435);
(β1, β2, β3, β4) = (log(1.5), log(0.7), log(1.3),− log(1.3)) ≈ (0.405,−0.357, 0.262,−0.262).
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Table B.5: Relative performance for the estimation of regression parameters is compared for (i) the complete case
analysis with simple random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-
SRS), (iii) a design-based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the
mean score estimation with adaptive sampling (MS-A) and the optimal sampling design (MS-O), where n = 800
subsample was drawn from the full cohort size of N = 4000. Results for the full cohort estimator based on complete
data are provided as a benchmark. Mean squared error (MSE) and its bias-variance decomposition are estimated from
1000 Monte Carlo replications, where the censoring rate was 50%. The adaptive and optimal sampling designs were
for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405.
Sample size Sampling Estimation Criterion Estimation performance by regression coefficient
α1 α2 α3 α4 α5 α6 β1 β2 β3 β4
n = 800
SRS
CC
√
MSE 0.262 0.239 0.220 0.206 0.199 0.191 0.228 0.286 0.101 0.101
Bias -0.030 -0.018 -0.016 -0.007 -0.016 -0.005 0.005 0.002 0.005 -0.004√
Var 0.260 0.238 0.220 0.206 0.198 0.191 0.228 0.286 0.101 0.101
N = 4000
MS
√
MSE 0.169 0.156 0.151 0.149 0.146 0.144 0.155 0.292 0.104 0.102
Bias -0.022 -0.008 -0.009 -0.008 -0.009 -0.004 0.004 0.001 0.007 -0.004√
Var 0.167 0.156 0.151 0.148 0.145 0.144 0.155 0.292 0.103 0.102
Balanced MS
√
MSE 0.202 0.196 0.193 0.191 0.189 0.190 0.194 0.396 0.145 0.141
Bias -0.017 -0.006 -0.009 -0.007 -0.007 0.000 0.010 0.008 -0.002 0.002√
Var 0.201 0.195 0.193 0.190 0.189 0.190 0.194 0.396 0.145 0.141
Adaptive MS
√
MSE 0.154 0.149 0.145 0.142 0.139 0.140 0.147 0.280 0.099 0.102
Bias -0.010 -0.001 -0.003 -0.003 -0.003 0.001 0.006 -0.010 0.005 -0.003√
Var 0.154 0.149 0.145 0.142 0.139 0.140 0.147 0.280 0.099 0.102
Oracle MS
√
MSE 0.147 0.139 0.137 0.135 0.131 0.131 0.133 0.261 0.096 0.095
Bias -0.004 0.006 0.003 0.004 0.003 0.007 0.005 -0.018 0.002 -0.005√
Var 0.147 0.139 0.137 0.135 0.131 0.131 0.133 0.260 0.096 0.095
Full cohort analysis
√
MSE 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
Bias -0.010 0.000 -0.003 -0.002 -0.005 -0.002 0.003 -0.001 -0.000 0.000√
Var 0.107 0.096 0.091 0.085 0.080 0.079 0.094 0.116 0.044 0.042
(α1, α2, α3, α4, α5, α6) = (−3.410,−3.027,−2.641,−2.249,−1.849,−1.435);
(β1, β2, β3, β4) = (log(1.5), log(0.7), log(1.3),− log(1.3)) ≈ (0.405,−0.357, 0.262,−0.262).
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Table B.6: Relative performance for the estimation of regression parameters is compared for (i) the complete case
analysis with simple random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-
SRS), (iii) a design-based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the
mean score estimation with adaptive sampling (MS-A) and the optimal sampling design (MS-O), where n = 400
subsample was drawn from the full cohort size of N = 2000. Results for the full cohort estimator based on complete
data are provided as a benchmark. Mean squared error (MSE) and its bias-variance decomposition are estimated from
1000 Monte Carlo replications, where the censoring rate was 50%. The adaptive and optimal sampling designs were
for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405.
Sample size Sampling Estimation Criterion Estimation performance by regression coefficient
α1 α2 α3 α4 α5 α6 β1 β2 β3 β4
n = 400
SRS
CC
√
MSE 0.381 0.342 0.323 0.288 0.281 0.284 0.324 0.419 0.145 0.147
Bias -0.049 -0.044 -0.039 -0.025 -0.020 -0.019 -0.011 0.029 0.006 -0.005√
Var 0.378 0.340 0.321 0.287 0.280 0.283 0.324 0.418 0.145 0.147
N = 2000
MS
√
MSE 0.267 0.245 0.232 0.224 0.217 0.223 0.237 0.434 0.150 0.156
Bias -0.072 -0.050 -0.044 -0.036 -0.028 -0.031 0.020 0.027 0.005 -0.004√
Var 0.258 0.240 0.228 0.221 0.215 0.221 0.236 0.433 0.150 0.156
Balanced MS
√
MSE 0.278 0.275 0.267 0.266 0.263 0.266 0.276 0.550 0.200 0.198
Bias -0.024 -0.018 -0.019 -0.014 -0.006 -0.003 0.026 -0.005 0.013 -0.005√
Var 0.277 0.274 0.266 0.265 0.263 0.266 0.275 0.550 0.199 0.198
Adaptive MS
√
MSE 0.233 0.220 0.211 0.210 0.207 0.210 0.214 0.421 0.152 0.148
Bias -0.019 -0.014 -0.016 -0.012 -0.005 -0.007 0.004 0.006 0.010 -0.016√
Var 0.232 0.219 0.210 0.209 0.207 0.210 0.214 0.421 0.152 0.147
Oracle MS
√
MSE 0.215 0.204 0.195 0.195 0.186 0.195 0.202 0.383 0.134 0.136
Bias -0.021 -0.012 -0.014 -0.010 -0.004 -0.008 -0.012 0.021 0.001 -0.004√
Var 0.214 0.203 0.194 0.194 0.186 0.195 0.202 0.382 0.134 0.136
Full cohort analysis
√
MSE 0.152 0.136 0.124 0.121 0.112 0.118 0.129 0.172 0.062 0.061
Bias -0.009 -0.005 -0.008 -0.006 -0.002 -0.008 -0.004 0.010 0.001 -0.001√
Var 0.152 0.136 0.124 0.121 0.112 0.118 0.129 0.171 0.062 0.061
(α1, α2, α3, α4, α5, α6) = (−3.410,−3.027,−2.641,−2.249,−1.849,−1.435);
(β1, β2, β3, β4) = (log(1.5), log(0.7), log(1.3),− log(1.3)) ≈ (0.405,−0.357, 0.262,−0.262).
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Table B.7: Relative performance for the estimation of regression parameters is compared for (i) the complete case
analysis with simple random sampling (CC-SRS), (ii) the mean score method with simple random sampling (MS-
SRS), (iii) a design-based estimation with balanced sample, equivalent to the mean score (MS-BAL), (iv & v) the
mean score estimation with adaptive sampling (MS-A) and the optimal sampling design (MS-O), where n = 400
subsample was drawn from the full cohort size of N = 8000. Results for the full cohort estimator based on complete
data are provided as a benchmark. Mean squared error (MSE) and its bias-variance decomposition are estimated from
1000 Monte Carlo replications, where the censoring rate was 50%. The adaptive and optimal sampling designs were
for efficient estimation of X1 with β1 = log(1.5) ≈ 0.405.
Sample size Sampling Estimation Criterion Estimation performance by regression coefficient
α1 α2 α3 α4 α5 α6 β1 β2 β3 β4
n = 400
SRS
CC
√
MSE 0.381 0.334 0.316 0.289 0.281 0.280 0.321 0.419 0.155 0.149
Bias -0.042 -0.037 -0.034 -0.020 -0.014 -0.004 -0.001 0.001 0.012 -0.007√
Var 0.379 0.332 0.314 0.288 0.280 0.280 0.321 0.419 0.154 0.149
N = 8000
MS
√
MSE 0.236 0.211 0.208 0.201 0.199 0.200 0.200 0.435 0.162 0.157
Bias -0.071 -0.043 -0.034 -0.028 -0.022 -0.017 0.027 -0.000 0.015 -0.009√
Var 0.225 0.206 0.205 0.199 0.198 0.200 0.198 0.435 0.161 0.157
Balanced MS
√
MSE 0.272 0.271 0.271 0.268 0.269 0.270 0.265 0.572 0.211 0.207
Bias -0.012 -0.009 -0.007 -0.004 0.004 0.014 0.021 -0.002 0.007 -0.017√
Var 0.272 0.271 0.271 0.268 0.269 0.270 0.264 0.572 0.211 0.207
Adaptive MS
√
MSE 0.196 0.194 0.195 0.193 0.194 0.195 0.190 0.417 0.153 0.148
Bias -0.009 -0.008 -0.007 -0.005 -0.001 0.004 0.002 -0.014 0.008 0.001√
Var 0.196 0.193 0.195 0.193 0.194 0.195 0.189 0.417 0.153 0.148
Oracle MS
√
MSE 0.178 0.174 0.170 0.170 0.171 0.172 0.174 0.362 0.134 0.133
Bias -0.006 -0.004 -0.002 -0.002 0.002 0.005 -0.005 -0.010 -0.001 0.008√
Var 0.178 0.174 0.170 0.170 0.171 0.172 0.174 0.362 0.134 0.133
Full cohort analysis
√
MSE 0.076 0.071 0.063 0.060 0.057 0.055 0.067 0.085 0.030 0.031
Bias -0.002 -0.001 -0.001 -0.001 0.001 0.001 0.000 -0.003 0.001 0.000√
Var 0.076 0.071 0.063 0.060 0.057 0.055 0.067 0.085 0.030 0.031
(α1, α2, α3, α4, α5, α6) = (−3.410,−3.027,−2.641,−2.249,−1.849,−1.435);
(β1, β2, β3, β4) = (log(1.5), log(0.7), log(1.3),− log(1.3)) ≈ (0.405,−0.357, 0.262,−0.262).
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B.2 Two-phase analysis with modified sampling design in the NWTS data example
Table B.8: Modification of the proposed mean score sampling design for the discrete-time survival analysis of the
National Wilms Tumor Study to include all individuals regardless of the time to censoring (N = 3915). Similarly
to Table 2, we compare five different methods (CC-SRS, MS-SRS, MS-BAL, MS-A, MS-O) as well as two modified
designs by under-sampling the censored individuals not relapsing before the end of the follow-up period in the balanced
and the pilot sample†,‡. The optimal sampling design was estimated using the full cohort data. The MS-A and MS-O
designs are for efficient estimation of the interaction effect between unfavorable histology and disease stage. Results
from the full cohort analysis with complete data are presented as a benchmark. Mean squared error and its bias-
variance decomposition are estimated using 1000 phase two samples of n = 400 from the full cohort (N = 3915).
Sampling Estimation Criterion Baseline hazard in complementary log-log scale Regression coefficient0.5yr 1yr 1.5yr 2yr 2.5yr 3yr UH1 Stage2 Age3 dTmr4 U∗S5
Full cohort analysis Ref. -4.074 -3.916 -4.373 -5.037 -5.378 -5.737 1.087 0.287 0.064 0.031 0.632
SRS
CC
√
MSE 0.469 0.460 0.479 0.706 1.537 2.601 0.640 0.340 0.050 0.034 0.763
Bias -0.074 -0.067 -0.074 -0.136 -0.283 -0.694 -0.025 -0.011 -0.001 0.001 0.070√
Var 0.463 0.455 0.473 0.693 1.511 2.507 0.640 0.340 0.050 0.034 0.759
MS
√
MSE 0.433 0.428 0.429 0.580 1.464 2.587 0.635 0.355 0.051 0.037 0.815
Bias -0.028 -0.023 -0.035 -0.109 -0.330 -0.829 -0.102 -0.005 0.001 0.001 0.131√
Var 0.432 0.428 0.428 0.570 1.426 2.450 0.627 0.355 0.051 0.037 0.804
Balanced MS
√
MSE 0.512 0.504 0.493 0.485 0.482 0.481 0.460 0.437 0.068 0.043 0.712
Bias -0.123 -0.105 -0.088 -0.077 -0.071 -0.067 0.048 0.046 0.018 0.004 -0.051√
Var 0.497 0.492 0.485 0.479 0.477 0.476 0.457 0.435 0.066 0.042 0.710
Balanced MS
√
MSE 0.436 0.428 0.419 0.412 0.410 0.409 0.403 0.371 0.061 0.036 0.614
(†modified) Bias -0.090 -0.075 -0.062 -0.054 -0.049 -0.046 0.038 0.009 0.016 0.003 0.002√
Var 0.426 0.421 0.415 0.409 0.407 0.406 0.401 0.371 0.059 0.036 0.614
Adaptive MS
√
MSE 0.350 0.343 0.336 0.331 0.329 0.327 0.326 0.313 0.045 0.028 0.519
Bias -0.071 -0.060 -0.052 -0.047 -0.044 -0.042 -0.010 0.002 0.009 0.003 0.056√
Var 0.342 0.337 0.332 0.327 0.326 0.325 0.326 0.313 0.044 0.027 0.516
Adaptive MS
√
MSE 0.342 0.336 0.329 0.324 0.323 0.322 0.290 0.266 0.042 0.027 0.448
(‡modified) Bias -0.060 -0.052 -0.045 -0.040 -0.038 -0.036 -0.003 -0.014 0.009 0.002 0.057√
Var 0.337 0.332 0.326 0.322 0.320 0.320 0.290 0.265 0.041 0.027 0.445
Oracle MS
√
MSE 0.269 0.267 0.264 0.261 0.261 0.260 0.234 0.232 0.035 0.022 0.379
Bias -0.007 -0.009 -0.008 -0.006 -0.006 -0.005 0.006 0.008 0.002 -0.000 0.030√
Var 0.269 0.267 0.264 0.261 0.261 0.260 0.234 0.232 0.034 0.022 0.377
1 Unfavorable histology versus favorable; 2 disease stage III/IV versus I/II;
3 year at diagnosis; 4 tumor diameter (cm); 5 interaction effect between UH and Stage.
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Table B.9: Modification of the proposed mean score sampling design for the two-phase continuous-time Cox model
analysis of time to relapse in the National Wilms Tumor Study to include all individuals regardless of the time to
censoring (N = 3915). Similarly to Table 3, we used inverse probability weights (IPW) for the two-phase analysis
for four different sampling designs for the second phase; (i) simple random sampling (SRS), (ii) balanced sampling,
(iii & iv) the proposed adaptive and oracle sampling designs as well as two modified designs by under-sampling the
censored individuals not relapsing before the end of the follow-up period in the balanced and the pilot sample.†,‡ Here,
the adaptive and oracle designs were determined by the mean score method for the discrete-time survival analysis. The
target parameter for the mean score design was the interaction between unfavorable histology and late stage disease.
Mean squared error and its bias-variance decomposition are estimated from 1000 phase two subsamples of n = 400
from the full cohort. Reference parameters estimates are from the full cohort analysis using the continuous-time Cox
model with complete data on all subjects.
Sampling Criterion Estimation performance by regressorUH1 Stage2 Age3 dTmr4 U∗S5
Full cohort analysis Ref. 1.050 0.297 0.065 0.021 0.620
SRS
√
MSE 0.444 0.322 0.049 0.033 0.648
Bias -0.092 0.009 -0.000 0.000 0.115√
Var 0.434 0.322 0.049 0.033 0.638
Balanced
√
MSE 0.478 0.519 0.074 0.049 0.752
Bias 0.061 0.032 0.016 0.006 -0.037√
Var 0.474 0.518 0.072 0.048 0.751
Balanced
√
MSE 0.440 0.434 0.065 0.043 0.643
(†modified) Bias 0.039 0.012 0.011 0.008 0.025√
Var 0.438 0.434 0.065 0.043 0.643
Adaptive
√
MSE 0.338 0.373 0.052 0.034 0.541
Bias -0.001 0.005 0.005 0.002 0.035√
Var 0.338 0.373 0.052 0.034 0.540
Adaptive
√
MSE 0.328 0.325 0.050 0.031 0.493
(†modified) Bias -0.023 0.000 0.008 0.002 0.053√
Var 0.327 0.325 0.049 0.031 0.491
Oracle
√
MSE 0.255 0.250 0.041 0.025 0.396
Bias -0.001 -0.006 0.004 0.001 0.043√
Var 0.255 0.250 0.041 0.025 0.393
1 Unfavorable histology versus favorable; 2 disease stage III/IV versus I/II;
3 year at diagnosis; 4 tumor diameter (cm); 5 interaction effect between UH and Stage.
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